Perspectives of liquid chromatography coupled to low-and high-resolution mass spectrometry for screening, identification, and quantification of drugs in clinical and forensic toxicology

Therapeutic Drug Monitoring

Volumn 32, Issue 3, 2010, Pages 324-327

  Maurer, Hans H ^a  

^a SAARLAND UNIVERSITY   (Germany)

Author keywords

Clinical toxicology; Forensic toxicology; LC MS MS; Quantification; Screening

Indexed keywords

DIURETIC AGENT; HYDROMORPHONE; MORPHINE; OPIATE; TETRAHYDROCANNABINOLIC ACID;

ACCURACY; CONFERENCE PAPER; DOPING; DRUG ABUSE; FORENSIC TOXICOLOGY; HUMAN; ION TRAP MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY; MASS FRAGMENTOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TANDEM MASS SPECTROMETRY; TIME OF FLIGHT MASS SPECTROMETRY; TOXICOKINETICS;

CHROMATOGRAPHY, LIQUID; FORENSIC TOXICOLOGY; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; MASS SPECTROMETRY; PHARMACEUTICAL PREPARATIONS; POISONS; SUBSTANCE ABUSE DETECTION;

EID: 77952951757     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181dca295     Document Type: Conference Paper

References (53)

1. Maurer HH. Position of chromatographic techniques in screening for detection of drugs or poisons in clinical and forensic toxicology and/or doping control. Clin Chem Lab Med. 2004;42:1310-1324.
2. Maurer HH. Multi-analyte procedures for screening for and quantification of drugs in blood, plasma, or serum by liquid chromatography-single stage or tandem mass spectrometry (LC-MS or LC-MS/MS) relevant to clinical and forensic toxicology. Clin Biochem. 2005;38:310-318.
3. Maurer HH. Advances in analytical toxicology: current role of liquid chromatography-mass spectrometry for drug quantification in blood and oral fluid. Anal Bioanal Chem. 2005;381:110-118.
4. Maurer HH. Hyphenated mass spectrometric techniques\indispensable tools in clinical and forensic toxicology and in doping control. J Mass Spectrom. 2006;41:1399-1413.
5. Maurer HH. Demands on scientific studies in clinical toxicology. Forensic Sci Int. 2007;165:194-198.
6. Maurer HH. Current role of liquid chromatography-mass spectrometry in clinical and forensic toxicology. Anal Bioanal Chem. 2007;388: 1315-1325.
7. Maurer HH. Mass spectrometric approaches in impaired driving toxicology. Anal Bioanal Chem. 2009;393:97-107.
8. John H, Worek F, Thiermann H. LC-MS-based procedures for monitoring of toxic organophosphorus compounds and verification of pesticide and nerve agent poisoning. Anal Bioanal Chem. 2008;391:97-116.
9. Laloup M, Samyn N, Maes V. Bio-analysis of forensically relevant drugs in alternative matrices by liquid chromatography-tandem mass spec-trometry. Verh K Acad Geneeskd Belg. 2008;70:347-367.
10. Tolonen A, Turpeinen M, Pelkonen O. Liquid chromatography-mass spectrometry in in vitro drug metabolite screening. Drug Discov Today. 2009;14:120-133.
11. Mueller CA, Weinmann W, Dresen S, et al. Development of a multi-target screening analysis for 301 drugs using a QTrap liquid chromatography/tandem mass spectrometry system and automated library searching. Rapid Commun Mass Spectrom. 2005;19:1332-1338.
12. Dresen S, Gergov M, Politi L, et al. ESI-MS/MS library of 1,253 compounds for application in forensic and clinical toxicology. Anal Bioanal Chem. 2009;395:2521-2526.
13. Sauvage FL, Saint-Marcous F, Duretz B, et al. Screening of drugs and toxic compounds with liquid chromatography-linear ion trap tandem mass spectrometry. Clin Chem. 2006;52:1735-1742.
14. Politi L, Morini L, Polettini A. A direct screening procedure for diuretics in human urine by liquid chromatography-tandem mass spectrometry with information dependent acquisition. Clin Chim Acta. 2007;386: 46-52.
15. Nordgren HK, Beck O. Direct screening of urine for MDMA and MDA by liquid chromatography-tandem mass spectrometry. J Anal Toxicol. 2003; 27:15-19.
16. Nordgren HK, Beck O. Multicomponent screening for drugs of abuse: direct analysis of urine by LC-MS-MS. Ther Drug Monit. 2004; 26:90-97.
17. Nordgren HK, Holmgren P, Liljeberg P, et al. Application of direct urine LC-MS-MS analysis for screening of novel substances in drug abusers. J Anal Toxicol. 2005;29:234-239.
18. Andersson M, Gustavsson E, Stephanson N, et al. Direct injection LC-MS/MS method for identification and quantification of amphetamine, methamphetamine, 3,4-methylenedioxyamphetamine and 3,4-methylene-dioxymethamphetamine in urine drug testing. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;861:22-28.
19. Gustavsson E, Andersson M, Stephanson N, et al. Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. J Mass Spectrom. 2007;42:881-889.
20. Stephanson N, Josefsson M, Kronstrand R, et al. Accurate identification and quantification of 11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid in urine drug testing: evaluation of a direct high efficiency liquid chromatographic-mass spectrometric method. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;871:101-108.
21. Stephanson N, Dahl H, Helander A, et al. Direct quantification of ethyl glucuronide in clinical urine samples by liquid chromatography-mass spectrometry. Ther Drug Monit. 2002;24:645-651.
22. Stephanson N, Helander A, Beck O. Alcohol biomarker analysis: simultaneous determination of 5-hydroxytryptophol glucuronide and 5-hydroxyindoleacetic acid by direct injection of urine using ultra-performance liquid chromatography-tandem mass spectrometry. J Mass Spectrom. 2007;42:940-949.
23. Bjornstad K, Beck O, Helander A. A multi-component LC-MS/MS method for detection of ten plant-derived psychoactive substances in urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;877: 1162-1168.
24. Allen KR, Azad R, Field HP, et al. Replacement of immunoassay by LC tandem mass spectrometry for the routine measurement of drugs of abuse in oral fluid. Ann Clin Biochem. 2005;42:277-284.
25. Dams R, Huestis MA, Lambert WE, et al. Matrix effect in bio-analysis of illicit drugs with LC-MS/MS: influence of ionization type, sample preparation, and biofluid. J Am Soc Mass Spectrom. 2003;14: 1290-1294.
26. Allen KR. Interference by venlafaxine ingestion in the detection of tramadol by liquid chromatography linked to tandem mass spectrometry for the screening of illicit drugs in human urine. Clin Toxicol (Phila). 2006;44:147-153.
27. Sauvage FL, Gaulier JM, Lachatre G, et al. Pitfalls and prevention strategies for liquid chromatography-tandem mass spectrometry in the selected reaction-monitoring mode for drug analysis. Clin Chem. 2008;54: 1519-1527.
28. Maurer HH, Pfleger K, Weber AA. Mass Spectral and GC Data of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, 3rd ed. Weinheim: Wiley-VCH; 2007.
29. Maurer HH, Pfleger K, Weber AA. Mass Spectral Library of Drugs, Poisons, Pesticides, Pollutants and Their Metabolites, 4th rev ed. Weinheim: Wiley-VCH; 2007.
30. Pfleger K, Maurer H, Weber A. Mass Spectral and GC Data of Drugs, Poisons, and their Metabolites, 1st ed. Weinheim: VCH Publisher; 1985.
31. Gergov M, Boucher B, Ojanpera I, et al. Toxicological screening of urine for drugs by liquid chromatography/time-of-flight mass spectrometry with automated target library search based on elemental formulas. Rapid Commun Mass Spectrom. 2001;15:521-526.
32. Pelander A, Ojanpera I, I, Laks S, et al. Toxicological screening with formula-based metabolite identification by liquid chromatography/time-of-flight mass spectrometry. Anal Chem. 2003;75:5710-5718.
33. Ojanpera I, Pelander A, Laks S, et al. Application of accurate mass measurement to urine drug screening. J Anal Toxicol. 2005;29: 34-40. (Pubitemid 40128943)
34. Ojanpera S, Pelander A, Pelzing M, et al. Isotopic pattern and accurate mass determination in urine drug screening by liquid chromatography/time-of- flight mass spectrometry. Rapid Commun Mass Spectrom. 2006; 20:1161-1167.
35. Kolmonen M, Leinonen A, Pelander A, et al. A general screening method for doping agents in human urine by solid phase extraction and liquid chromatography/time-of-flight mass spectrometry. Anal Chim Acta. 2007; 585:94-102.
36. Pelander A, Ristimaa J, Rasanen I, et al. Screening for basic drugs in hair of drug addicts by liquid chromatography/time-of-flight mass spectrometry. Ther Drug Monit. 2008;30:717-724.
37. Lee HK, Ho CS, Iu YP, et al. Development of a broad toxicological screening technique for urine using ultra-performance liquid chromatog-raphy and time-of-flight mass spectrometry. Anal Chim Acta. 2009;649: 80-90.
38. Staack RF, Maurer HH. Metabolism of designer drugs of abuse. Curr Drug Metab. 2005;6:259-274.
39. Philipp AA, Wissenbach DK, Zoerntlein SW, et al. Studies on the metabolism of mitragynine, the main alkaloid of the herbal drug Kratom, in rat and human urine using liquid chromatography-linear ion trap mass spectrometry. J Mass Spectrom. 2009;44:1249-1261.
40. Philipp AA, Wissenbach DK, Weber AA, et al. Use of liquid chromatography coupled to low and high resolution linear ion trap mass spectrometry for studying the metabolism of paynantheine, an alkaloid of the herbal drug Kratom in rat and human urine. Anal Bioanal Chem. 2010; 396:2379-2391.
41. Maurer HH, Sauer C, Theobald DS. Toxicokinetics of drugs of abuse: current knowledge of the isoenzymes involved in the human metabolism of tetrahydrocannabinol, cocaine, heroin, morphine, and codeine. Ther Drug Monit. 2006;28:447-453.
42. Meyer MR, Peters FT, Maurer HH. The role of human hepatic cytochrome p450 isozymes in the metabolism of racemic 3,4-methylenedioxy-methamphetamine and its enantiomers. Drug Metab Dispos. 2008;36: 2345-2354.
43. Meyer MR, Maurer HH. Enantioselectivity in the methylation of the catecholic phase-I metabolites of methylenedioxy designer drugs and their capability to inhibit COMT catalyzed dopamine 3-methylation. Chem Res Toxicol. 2009;22:1205-1211.
44. Schwaninger AE, Meyer MR, Zapp J, et al. The role of human UDP-glucuronyltransferases on the formation of the methylenedioxyme- thamphetamine (ecstasy) phase II metabolites R-and S-3-methoxyme-thamphetamine 4-O-glucuronides. Drug Metabol Dispos. 2009;37: 2212-2220.
45. Pelander A, Tyrkko E, Ojanpera I. In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening. Rapid Commun Mass Spectrom. 2009;23:506-514.
46. Beyer J, Peters FT, Kraemer T, et al. Detection and validated quantification of toxic alkaloids in human blood plasma\comparison of LC-APCI-MS with LC-ESI-MS/MS. J Mass Spectrom. 2007;42:621-633.
47. Shah VP, Midha KK, Findlay JW, et al. Bioanalytical method validation\a revisit with a decade of progress. Pharm Res. 2000;17: 1551-1557.
48. US Department of Health and Human Services FaDA. Guidance for Industry, Bioanalytical Method Validation 2001. Available at: http://www. fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070107.pdf. Accessed March 30, 2010.
49. Peters FT, Maurer HH. Bioanalytical method validation and its implications for forensic and clinical toxicology\a review. Accred Qual Assur. 2002;7:441-449.
50. Peters FT, Drummer OH, Musshoff F. Validation of new methods. Forensic Sci Int. 2007;165:216-224.
51. Smink BE, Brandsma JE, Dijkhuizen A, et al. Quantitative analysis of 33 benzodiazepines, metabolites and benzodiazepine-like substances in whole blood by liquid chromatography-(tandem) mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2004;811:13-20.
52. Ishida T, Kudo K, Hayashida M, et al.Rapid and quantitative screening method for 43 benzodiazepines and their metabolites, zolpidem and zopiclone in human plasma by liquid chromatography/mass spectrometry with a small particle column. J Chromatogr B Analyt Technol Biomed Life Sci. 2009;
53. Wagner M, Varesio E, Hopfgartner G. Ultra-fast quantitation of saquinavir in human plasma by matrix-assisted laser desorption/ionization and selected reaction monitoring mode detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872: 68-76.